Cell line · CVCL_0013
Papers107
1 to 20 of 107
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Multi-omics-driven personalized management of advanced HCC. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Impact of IL-21 on CAR T-cell manufacturing: phenotypic, metabolic, and functional outcomes. | Front Immunol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Dynamic Switching of Apoptosis-Modulating Bim Heterodimers in Response to BH3 Mimetics in Xenograft Models of Hematologic Malignancies. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Dual regulation of CXCR6+CD8+ T cells modulates cytotoxic and exhaustion-associated programs during prostate cancer progression. | J Immunother Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting Menin in T-lineage Acute Lymphoblastic Leukemia. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| IMPDH inhibition enhances cytarabine efficacy in SAMHD1-expressing leukaemia cells via guanine nucleotide depletion. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Discovery of SKP2-Recruiting PROTACs for Target Protein Degradation. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Distinct Regulation of the ARF and TAp73 Tumor Suppressor Genes by the Transcription Factor E2F1 Enables Discrimination of Cancer Cells from Normal Growing Cells. | Cells | 2026 | Its Methods give the RRID and name the line | PubMed | |
| HIV-1 establishes immediate latency in T cells expressing the viral Nef protein. | FEBS Open Bio | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Activity of Direct KRAS(G12C) Inhibitors in Preclinical Models of Pediatric Cancer. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Dimerization-dependent NOTCH receptor transactivation unveils a class of highly selective NOTCH signalling inhibitors. | FEBS J | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Multiomics Profiling of T-cell Leukemia and Lymphoma Enables Targeted Therapeutic Discovery. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Chronic ISG15 Exposure Accelerates CD8+ T-cell Dysfunction while Increasing PD-1 Blockade Sensitivity in Oral Squamous Cell Carcinoma. | Cancer Immunol Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Intron-oriented HTLV-1 integration in an adult T-cell leukemia/lymphoma cell line sustains expression of intact ift81 mRNA. | FEBS Lett | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Development of a Novel Bifunctional Anti-CD47 Fusion Protein with Improved Efficacy and a Favorable Safety Profile. | Mol Cancer Ther | 2025 | Its Methods give the RRID and name the line | PubMed | |
| B7H6 is the predominant activating ligand driving natural killer cell-mediated killing in patients with liquid tumours: evidence from clinical, in silico, in vitro, and in vivo studies. | EBioMedicine | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Peculiar transcriptional reprogramming with functional impairment of dendritic cells upon exposure to transformed HTLV-1-infected cells. | PLoS Pathog | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Cannabinoid combination targets NOTCH1-mutated T-cell acute lymphoblastic leukemia through the integrated stress response pathway. | Elife | 2024 | Its Methods give the RRID and name the line | PubMed | |
| HTS384 NCI60: The Next Phase of the NCI60 Screen. | Cancer Res | 2024 | Cellosaurus cites it, and its Methods give the RRID and name the line | PubMed | |
| Soluble CD46 as a diagnostic marker of hepatic steatosis. | EBioMedicine | 2024 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0013/papers